Komori
Abist (6087) · FactAdvanced

Growth in revenue from the hydrogen water business and a reduction in operating loss

First written in FY2016-Q3. 5 of 34 entries say "Advanced", first in FY2016. Latest entry: 2026-08-07.

34entries
11years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2017-Q2 – FY2023-Q3OtherFY2024-Q1 – FY2025-H12016: 220162017: 420172018: 420182019: 320192020: 320202021: 420212022: 420222023: 420232024: 220242025: 220252026: 22026
Same theme, other companies
Revenue Growth and Operating Loss Reduction in the Hydrogen Water and Beauty and Health Products BusinessA theme 3 companies write about · 0 as a headwind · 3 as a tailwind

0 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  2. FY2025AdvancedAnnual report

    「Reduced shipping costs, primarily through more efficient delivery methods, contributed to segment profit.」

    Although revenue in the beauty and health products manufacturing and sales business declined 1.9% year on year, the business changed from recording an operating loss to operating profit of ¥23 million, with an operating margin of 15.9%. More efficient delivery methods and lower shipping costs contributed to profit.
  3. FY2025-H1Stable OEM sales, but wider loss due to lower direct-to-consumer sales and higher personnel expensesAnnual report

    「While OEM sales remained stable, revenue was ¥25 million, down 5.1% year on year, and the segment loss (operating loss) was ¥13 million, compared with a segment loss (operating loss) of ¥9 million in the same period of the previous year, due to lower sales in the direct-to-consumer business and higher personnel and other expenses.」

    In the beauty and health products manufacturing and sales business, OEM sales remained stable, while revenue fell 5.1% and the operating loss widened from ¥9 million to ¥13 million due to lower revenue from the direct-to-consumer business and higher personnel expenses.
  4. FY2024-Q2Higher revenue but wider loss following merger by absorptionAnnual report

    「In this segment, revenue was ¥26 million, up 132.5% year on year, and the segment loss (operating loss) was ¥9 million, compared with a segment loss (operating loss) of ¥2 million in the same period of the previous year, following the merger by absorption of subsidiary 株式会社アビストH&F on 1 February 2023.」

    In the beauty and health products manufacturing and sales business, revenue increased 132.5% year on year in the cumulative second quarter following the merger by absorption, while the operating loss widened from ¥2 million in the same period of the previous year to ¥9 million.
  5. FY2024-Q1Operating loss recorded in the first quarterAnnual report

    「In this segment, progress was made in reducing expenses. Revenue was ¥14 million and the segment loss (operating loss) was ¥3 million.」

    In the beauty and health products manufacturing and sales business, expense reductions progressed, while revenue was ¥14 million and the operating loss was ¥3 million in the first quarter.
  6. FY2023AdvancedAnnual report

    「In this segment, revenue was ¥128 million, segment profit (operating profit) was ¥11 million, and the segment profit (operating profit) margin was 8.6%, due to a decline in orders for OEM products.」

    The beauty and health products manufacturing and sales business moved from recording an operating loss through the previous quarter to operating profit of ¥11 million, with an operating margin of 8.6%, in the current fiscal year.
  7. FY2023-Q3Continued decline in OEM orders and operating loss recordedAnnual report

    「In this segment, revenue was ¥57 million and the segment loss (operating loss) was ¥19 million, due to a decline in orders for OEM products.」

    In the beauty and health products manufacturing and sales business, orders for OEM products continued to decline, resulting in revenue of ¥57 million and an operating loss of ¥19 million.
  8. FY2023-Q2RestatedAnnual report

    「In this segment, revenue was ¥11 million and the segment loss (operating loss) was ¥2 million, due to a decline in orders for OEM products.」

    In the beauty and health products manufacturing and sales business, orders for OEM products continued to decline, resulting in revenue of ¥11 million and an operating loss of ¥2 million.
  9. FY2023-Q1Revenue decline due to fewer OEM orders, but narrower loss due to expense reviewsAnnual report

    「In this segment, revenue was ¥16 million, down 64.7% year on year, due to a decline in orders for OEM products. Meanwhile, following a comprehensive review of expenses, the segment loss (operating loss) was ¥6 million, compared with a segment loss (operating loss) of ¥38 million in the same period of the previous year.」

    The beauty and health products manufacturing and sales business reported a significant revenue decline due to fewer orders for OEM products. However, the operating loss narrowed from ¥38 million to ¥6 million following a comprehensive review of expenses.
  10. FY2022RestatedAnnual report

    「In the third quarter, the Company discontinued beauty product sales and reviewed its earnings structure as part of a strategy of business selection and concentration. Revenue was ¥160 million, down 31.8% year on year, and the segment loss (operating loss) was ¥27 million, compared with an operating loss of ¥6 million in the same period of the previous year, due to lower sales resulting from the recall of some OEM products (jelly drinks) following quality nonconformities during the cumulative second-quarter period, as well as expenses associated with restructuring, including impairment losses on some equipment.」

    The discontinuation of beauty product sales and the review of the earnings structure continued through the full year. Revenue and earnings declined due to quality nonconformities, product recalls and restructuring costs.
  11. FY2022-Q3Beauty product sales discontinued; revenue and earnings declined amid restructuringAnnual report

    「In the third quarter, the Company discontinued beauty product sales and reviewed its earnings structure as part of a strategy of business selection and concentration. Revenue was ¥90 million, down 41.6% year on year, and the segment loss (operating loss) was ¥60 million, compared with a segment loss (operating loss) of ¥21 million in the same period of the previous year, due to lower sales resulting from the recall of some OEM products (jelly drinks) following quality nonconformities during the cumulative second-quarter period, as well as expenses associated with restructuring, including impairment losses on some equipment.」

    The Company discontinued beauty product sales and reviewed its earnings structure. Revenue declined and the operating loss widened due to product recalls resulting from quality nonconformities and restructuring costs, including impairment losses on equipment.
  12. FY2022-Q2Revenue decline and wider loss due to quality nonconformities and product recallsAnnual report

    「In this segment, revenue was ¥46 million, down 43.1% year on year, and the segment loss (operating loss) was ¥66 million, compared with a segment loss (operating loss) of ¥34 million in the same period of the previous year, due to the impact of recalling products following quality nonconformities in some OEM products (jelly drinks) and declining sales of beauty products.」

    The beauty and health products manufacturing and sales business reported lower revenue due to a product recall resulting from quality nonconformities in some OEM products and declining sales of beauty products. The operating loss widened from ¥34 million to ¥66 million.
  13. FY2022-Q1Large OEM orders offset sales decline, but higher personnel expenses widened the lossAnnual report

    「Although sales from television shopping broadcasts of beauty products declined, the decrease was offset by orders for large-scale OEM contract manufacturing. However, personnel expenses increased as a result of these orders, resulting in revenue of ¥46 million, up 1.9% year on year, and a segment loss (operating loss) of ¥38 million, compared with a segment loss (operating loss) of ¥13 million in the same period of the previous year.」

    The decline in television-shopping sales was offset by orders for large-scale OEM contract manufacturing, but higher personnel expenses associated with the orders limited the increase in revenue and widened the operating loss from ¥13 million to ¥38 million.
  14. FY2021Full-year revenue decline, but narrower lossAnnual report

    「In this segment, sales from television shopping broadcasts of beauty products declined. Following OEM orders for hydrogenated water and a review of expenses, including advertising expenses, revenue was ¥235 million, down 9.1% year on year, and the segment loss (operating loss) was ¥6 million, compared with an operating loss of ¥48 million in the same period of the previous year.」

    Sales of beauty products through television shopping declined, resulting in a 9.1% decrease in full-year revenue. Meanwhile, the operating loss narrowed from ¥48 million to ¥6 million due to OEM orders and a review of expenses.
  15. FY2021-Q3Lower television-shopping sales, but narrower loss due to expense reviewsAnnual report

    「In this segment, sales from television shopping broadcasts of beauty products declined. Following a review of expenses, including advertising expenses, and OEM orders for hydrogenated water, revenue was ¥155 million, down 15.5% year on year, and the segment loss (operating loss) was ¥21 million, compared with a segment loss (operating loss) of ¥56 million in the same period of the previous year.」

    Sales of beauty products through television shopping declined, resulting in a 15.5% year-on-year decrease in revenue. Meanwhile, the operating loss narrowed from ¥56 million to ¥21 million due to OEM orders for hydrogenated water and a review of expenses.
  16. FY2021-Q2Lower sales, but narrower lossAnnual report

    「In this segment, sales from television shopping broadcasts of beauty products declined. Following a review of expenses, including advertising and sales promotion expenses, and OEM orders for hydrogenated water, revenue was ¥82 million, down 22.8% year on year, and the segment loss (operating loss) was ¥34 million, compared with a segment loss (operating loss) of ¥61 million in the same period of the previous year.」

    Sales of beauty products through television shopping declined, resulting in a 22.8% year-on-year decrease in revenue. Meanwhile, the operating loss narrowed from ¥61 million to ¥34 million due to OEM orders for hydrogenated water and a review of expenses.
  17. FY2021-Q1Narrower loss due to OEM orders and expense reviewsAnnual report

    「Although sales generated through televised shopping programs for beauty products declined, the Company’s review of expenses, including hydrogen-water OEM orders and advertising and promotional expenses, resulted in sales of ¥45 million, down 18.3% year on year, and a segment loss (operating loss) of ¥13 million, compared with a segment loss (operating loss) of ¥47 million in the same period of the previous year.」

    Although sales of beauty products through television shopping declined, the operating loss narrowed from ¥47 million in the same period of the previous year to ¥13 million due to OEM orders for hydrogenated water and a review of expenses.
  18. FY2020-Q3Continued wider loss despite higher beauty and health product sales due to advertising investmentAnnual report

    「In this segment, revenue was ¥184 million, up 49.1% year on year, while the segment loss (operating loss) was ¥56 million, compared with a segment loss (operating loss) of ¥29 million in the same period of the previous year, despite sales of beauty and health products and investment in advertising expenses, including television commercials.」

    Revenue from beauty and health products increased 49.1% year on year, while the operating loss widened from ¥29 million to ¥56 million due to investment in advertising expenses, including television commercials.
  19. FY2020-Q2Higher beauty and health product sales, but wider loss due to advertising investmentAnnual report

    「In this segment, sales of beauty and health products progressed steadily, while investment in advertising and promotional expenses, including television commercials, resulted in sales of ¥106 million, up 86.7% year on year, and a segment loss (operating loss) of ¥61 million, compared with a segment loss (operating loss) of ¥37 million in the same period of the previous year.」

    Although revenue from beauty and health products increased 86.7% year on year, the operating loss widened from ¥37 million to ¥61 million due to investment in advertising expenses, including television commercials.
  20. FY2020-Q1Wider loss due to increased beauty product sales and advertising investmentAnnual report

    「In this segment, sales were generated from the launch of beauty products, while investment in advertising and promotional expenses, including television commercials featuring talent, resulted in sales of ¥55 million, up 87.7% year on year, and a segment loss (operating loss) of ¥47 million, compared with a segment loss (operating loss) of ¥21 million in the same period of the previous year.」

    Although revenue increased 87.7% year on year following the launch of beauty product sales, the operating loss widened from ¥21 million to ¥47 million due to investment in advertising expenses, including television commercials.
  21. FY2019-Q3Beauty product sales launched; health product launch delayedAnnual report

    「In this segment, revenue from the launch of beauty product sales was recorded, while delays in launching new health products resulted in revenue of ¥123 million, down 8.6% year on year, and a segment loss (operating loss) of ¥29 million, compared with a segment loss (operating loss) of ¥19 million in the same period of the previous year.」

    Although sales were generated following the launch of beauty product sales, revenue declined due to delays in launching new health products, and the operating loss widened from the same period of the previous year.
  22. FY2019-Q2Revenue decline and wider loss due to fewer subscribers and delayed new-product launchesAnnual report

    「In this segment, revenue was ¥57 million, down 19.2% year on year, and the segment loss (operating loss) was ¥37 million, compared with a segment loss (operating loss) of ¥26 million in the same period of the previous year, due in part to a decline in winter subscribers to the hydrogenated-water subscription service and delays in the launch of new products.」

    In the beauty and health products manufacturing and sales business, the decline in winter subscribers to the hydrogenated-water subscription service and delays in new-product launches were cited as factors. Revenue fell 19.2%, and the operating loss widened from ¥26 million to ¥37 million.
  23. FY2019-Q1Revenue decline and wider loss due to market weaknessAnnual report

    「In this segment, sales declined as the hydrogenated-water-related market remained weak. Revenue was ¥29 million, down 20.3% year on year, and the segment loss (operating loss) was ¥21 million, compared with a segment loss (operating loss) of ¥11 million in the same period of the previous year.」

    In the beauty and health products manufacturing and sales business, revenue fell 20.3% year on year as the hydrogenated-water-related market remained weak, while the operating loss widened from ¥11 million to ¥21 million.
  24. FY2018Sales continued to decline, while the operating loss narrowedAnnual report

    「Sales remained sluggish due to the impact of negative media coverage concerning hydrogenated water in general. Revenue was ¥201 million, down 22.3% year on year, and the segment loss (operating loss) was ¥19 million, compared with a segment loss (operating loss) of ¥24 million in the same period of the previous year.」

    Although sales in the hydrogenated-water business continued to decline, the operating loss narrowed from ¥24 million to ¥19 million.
  25. FY2018-Q3Sales continued to decline, while the operating loss was flatAnnual report

    「In this segment, sales were sluggish due to the impact of negative media coverage concerning hydrogenated water generally. Net sales were ¥135 million, down 30.6% year on year, and the segment loss (operating loss) was ¥19 million, the same as the ¥19 million segment loss (operating loss) recorded in the same period of the previous year.」

    Sales in the hydrogenated-water business remained sluggish due to negative media coverage, declining 30.6% year on year. Meanwhile, the operating loss was ¥19 million, unchanged from the same period of the previous year.
  26. FY2018-Q2Sales continued to decline, while the operating loss was flatAnnual report

    「In this segment, sales were sluggish due to the impact of negative media coverage concerning hydrogenated water generally. Net sales were ¥70 million, down 39.0% year on year, and the segment loss (operating loss) was ¥26 million, the same as the ¥26 million segment loss (operating loss) recorded in the same period of the previous year.」

    Sales in the hydrogenated water business remained sluggish due to negative media coverage, falling 39.0% year on year. Meanwhile, the operating loss was ¥26 million, at the same level as in the previous year.
  27. FY2018-Q1Sales decline widened, while the operating loss was flatAnnual report

    「In this segment, sales were sluggish due to the impact of negative media coverage concerning hydrogenated water generally. Net sales were ¥36 million, down 44.7% year on year, and the segment loss (operating loss) was ¥11 million, the same as the ¥11 million segment loss (operating loss) recorded in the same period of the previous year.」

    The hydrogenated water business saw a 44.7% year-on-year decline in sales, with the decline widening. Meanwhile, the operating loss was ¥11 million, unchanged from the same period of the previous year.
  28. FY2017Sales continued to decline, while the operating loss narrowedAnnual report

    「Sales were sluggish due to the impact of negative media coverage concerning hydrogenated water generally. Net sales were ¥259 million, down 35.5% year on year, and the segment loss (operating loss) was ¥24 million, compared with a segment loss (operating loss) of ¥34 million in the same period of the previous year.」

    Sales in the hydrogenated water business continued to decline, but the operating loss narrowed from ¥34 million to ¥24 million.
  29. FY2017-Q3Sales continued to decline, while the operating loss narrowedAnnual report

    「At the consolidated subsidiary 株式会社アビストＨ＆Ｆ, which operates the hydrogenated water manufacturing and sales business, sales remained sluggish due to the continuing impact of negative media coverage concerning hydrogenated water generally, but profitability improved as various expenses were reviewed and reduced. Sales in the hydrogenated water manufacturing and sales business were ¥194 million, down 32.3% year on year. The segment loss (operating loss) was ¥19 million, compared with a segment loss (operating loss) of ¥45 million in the same period of the previous year.」

    Sales remained sluggish due to negative media coverage, and sales for the cumulative third quarter fell 32.3% year on year. Meanwhile, the operating loss narrowed from ¥45 million to ¥19 million through the review and reduction of various expenses.
  30. FY2017-Q2Sales began to decline, while the operating loss narrowedAnnual report

    「At the consolidated subsidiary 株式会社アビストＨ＆Ｆ, which operates the hydrogenated water manufacturing and sales business, sales were sluggish due to the impact of negative media coverage concerning hydrogenated water generally, but profitability improved as various expenses were reviewed and reduced. Sales in the hydrogenated water manufacturing and sales business were ¥116 million, down 20.9% year on year. The segment loss (operating loss) was ¥26 million, compared with a segment loss (operating loss) of ¥58 million in the same period of the previous year.」

    The hydrogenated water business shifted from its previous trend of rising sales to a 20.9% year-on-year decline due to the impact of negative media coverage. Meanwhile, the operating loss narrowed from ¥58 million to ¥26 million through the review and reduction of various expenses.
  31. FY2017-Q1AdvancedAnnual report

    「In this segment, net sales were ¥66 million, up 7.9% year on year. The segment loss (operating loss) was ¥11 million, compared with a segment loss (operating loss) of ¥33 million in the same period of the previous year.」

    Sales in the hydrogenated water business rose 7.9% year on year, while the operating loss narrowed from ¥33 million to ¥11 million.
  32. FY2016AdvancedAnnual report

    「In this segment, net sales totaled ¥402 million, up 90.3% year on year. Due partly to increased advertising expenses for media such as newspapers and radio aimed at improving product recognition, the segment loss (operating loss) was ¥34 million, compared with a segment loss (operating loss) of ¥189 million in the same period of the previous year.」

    Sales in the hydrogenated water business increased significantly, and the operating loss narrowed from ¥189 million to ¥34 million, although an operating loss was still recorded.
  33. FY2016-Q3First statedAnnual report

    「Net sales totaled ¥287 million, up 148.8% year on year. Advertising expenses for media such as newspapers and radio were incurred to improve product recognition, resulting in a segment loss (operating loss) of ¥45 million, compared with a segment loss (operating loss) of ¥161 million in the same period of the previous year.」

    The Company reported higher sales and a narrower operating loss in its hydrogenated water manufacturing and sales business.
Moved together

"Financial structure with an equity ratio of 72.2%" moved the same way as this thread, in the same document, in 5 of its 34 moves.

532222★123456
  1. ★This thread
  2. 1Financial structure with an equity ratio of 72.2%5×
  3. 2Progress in Revenue and Profit Growth3×
  4. 3Risk of deterioration in cost ratios and profit margins due to lower engineer utilization2×
  5. 4Increase in Engineer Rates2×
  6. 5Enhancing Technical Skills Through E-Learning Using Tablet Devices2×
  7. 6Recruitment, training and assignment of 123 new employees2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Abist yet. It last moved in the Earnings of 2026-08-07: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Growth in revenue from the hydrogen water business and a reduction in operating loss | ABIST Co.,Ltd. (6087) | Komori